March 2026: Novo Nordisk reported top-line REDEFINE-1 Phase 3 CagriSema data showing 22.7% mean body weight reduction at 52 weeks , demonstrating superiority over standalone semaglutide 2.4mg and confirming the semaglutide-plus-amylin combination as clinically competitive with tirzepatide
In the present study, we aimed to demonstrate the effect of GLP-1 analog on RGCs and the potential mechanisms both in vivo and in vitro
Recurrent hypoglycaemia can lead to hypoglycaemia unawareness , where warning symptoms diminish, increasing the risk of severe episodes
The coenzymes of this vitamin are highly unstable in light (6)
Those impulsive behaviours can return upon cessation, said Ms Feszczur rendering the holiday period, where people tend to overeat, drink and spend, a tricky time to go off these medicines
doi: 10.1038/nn1452, 155 WaddenT